Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin vs. Epirubicin TACE in Hepatocellular Carcinoma
NCT05053386Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of idarubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05053386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053386.